Official Protocol Title: NCT number: NCT03520959 25-May-2018 Document Date: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Subjects Following First-line Systemic Anti- cancer Therapy *NOTE: This Statistical Analysis Plan (SAP) exists only as a draft version, as the trial was terminated before SAP finalization. Immune Design C orp. IMDZ -04-1702 SAP Draft V1.0 for Protocol V2.0 Version Date: 2018- 05-25 Confidential 1 / 36 Statistical Analysis Plan Title: A Phase 3, Randomized, Double -blind, Placebo- controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally -advanced or Metastatic NY -ESO -1+ Synovial Sarcoma Subjects Following First- line Systemic Anti- cancer Therapy Protocol Number: IMDZ -04-1702 Study Drug: CMB305 (sequentially administered LV305 [lentiviral vector encoding New York esophageal squamous cell carcinoma -1 {NY - ESO -1} gene] and G305 [NY- ESO -1 recombinant protein plus glucopyranosyl lipid A stable emulsion {GLA -SE}]) Sponsor: Immune Design Corp. (IMDZ) 1616 Eastlake Ave.